Akili Interactive Labs, Inc.
125 Broad Street
About Akili Interactive Labs, Inc.
At Akili, we're in the process of building clinically-validated cognitive therapeutics, assessments, and diagnostics that look and feel like high-quality video games. Our aim is to develop a new type of Digital Medicine that can be deployed remotely directly to any patient anywhere, prescribed and tracked by physicians.
Akili was co-founded by PureTech, leading cognitive neuroscientists, and top-tier entertainment software creators. Our operational team is a mix of biomedical scientists and experts in medical device commercialization and interactive design.
CEO: Eddie Martucci, PhD
Chief Creative Officer: Matthew Omernick
18 articles with Akili Interactive Labs, Inc.
In addition to the planned BioNTech IPO, many other pharma and biotech companies in Europe, Asia and elsewhere shared news for the week.
PureTech’s Independent Affiliate Akili Announces Partnership with Shionogi to Develop and Commercialise Digital Therapeutics in Certain Asian Markets
Akili receives upfront payments totalling $20 million and has the potential to receive milestone payments for Japan and Taiwan commercialisation of up to an additional $105 million, in addition to substantial royalties on product sales
Akili and Shionogi Announce Strategic Partnership to Develop and Commercialize Digital Therapeutics in Key Asian Markets
Akili to Create First-of-its-kind International Digital Medicine Development and Commercial Platform
Akili Builds Medical Team with Newly Appointed Medical Affairs Leader and Formation of Clinical Advisory Committee in Preparation for Commercial Launch
Anil S. Jina, M.D., Joins Akili to Build and Lead Medical Affairs Team
Recently, BioSpace posted a question on its website, under the heading, “We Want to Hear from You! Top Life Sciences Trends.” Let’s take a look at the five trends survey participants mentioned.
Akili Announces Exclusive Licensing Agreement for New Digital Technology Integrating Neural Systems Targeting and Physical Activity as Novel Cognitive Dysfunction Treatment Platform
Developed by leading neuroscientists at the U.C. San Francisco, currently in multiple clinical trials
Akili Interactive has raised $13 million in new funding as an extension of its Series C financing, which was announced in May.
Andrew Huberman, researcher in the Stanford University Department of Neurobiology, is taking an unusual approach to investigating possible treatments for glaucoma and anxiety disorders—virtual reality.
There are generally two types of antidepressants on the market. They are selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). But there are still individuals who do not respond well to these drugs and the industry continues to work on developing...
5/9/2018Akili Interactive, headquartered in Boston, closed a $55 million Series C financing. Akili is a prescription digital medicine company. Its goal is to treat certain disorders via high-quality video games.
New Patents Issued in U.S. and Japan Broadly Cover Unique Digital Mechanism for Assessing and Improving Cognitive Function
AKL-T01 was shown to be safe in this study, with no serious adverse events observed.
Akili Announces Results From Pilot Study Showing Treatment With Project EVO Improves Cognitive Control In Children With Sensory Processing Dysfunction And Attentional Deficits
Akili And Pfizer Present Positive Data From Digital Biomarker Study To Detect Subtle Cognitive Changes In Healthy Subjects At Risk Of Developing Alzheimer’s Disease
PureTech Health Release: Operating Company Akili Raises $30.5 Million To Advance Product Development And Build Commercial Infrastructure